474709-85-8

Basic information

• Product Name: Cyclopropanamine, 1-(3,4-difluorophenyl)-
• Synonyms: Cyclopropanamine, 1-(3,4-difluorophenyl)-;trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl amine;1-(3,4-Difluorophenyl)cyclopropan-1-amine
• CAS NO: 474709-85-8
• Molecular Formula: C₉H₉F₂N
• Molecular Weight: 169.17
• Mol File: 474709-85-8.mol

Chemical Properties

• Boiling Point: 213.9°C at 760 mmHg
• Flash Point: 100°C
• Appearance: /
• Density: 1.283g/cm³
• Vapor Pressure: 0.16mmHg at 25°C
• Refractive Index: 1.545
• CAS DataBase Reference: Cyclopropanamine, 1-(3,4-difluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanamine, 1-(3,4-difluorophenyl)-(474709-85-8)
• EPA Substance Registry System: Cyclopropanamine, 1-(3,4-difluorophenyl)-(474709-85-8)

Safety Data

• Hazardous Substances Data: 474709-85-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopropanamine, 1-(3,4-difluorophenyl)is utilized as a pharmaceutical intermediate for the synthesis of various medicinal compounds. Its unique structure allows it to serve as a building block in the development of drugs targeting specific biological pathways or receptors, contributing to the discovery of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, Cyclopropanamine, 1-(3,4-difluorophenyl)is employed as a precursor in the production of pesticides and other crop protection agents. Its chemical properties enable it to be incorporated into molecules with bioactivity against pests or diseases, thereby enhancing crop yield and quality.
Used in Chemical Research:
Cyclopropanamine, 1-(3,4-difluorophenyl)also serves as a valuable research tool in organic and medicinal chemistry. Its unique cyclopropane and difluorophenyl moieties make it an interesting subject for studying reaction mechanisms, exploring new synthetic routes, and understanding the structure-activity relationships in biologically active molecules.

InChI:InChI=1/C9H9F2N/c10-7-2-1-6(5-8(7)11)9(12)3-4-9/h1-2,5H,3-4,12H2

Upstream product

• 64248-62-0 3,4-Difluorobenzonitrile 
• 925-90-6 ethylmagnesium bromide 

Downstream Products

• 474699-21-3 N₁-[1-(3,4-difluorophenyl)-cyclopropyl]-2-fluoro-4-[6-(1-trityl-1H-4-pyrazolyl)imidazo[1,2-a]pyridin-3-yl]benzamide 

Relevant articles and documents

Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector

The synthesis of novel series of sulfamoylbenzamides as HBV capsid assembly effector is reported. The structure was divided into five parts which were independently modified as part of our lead optimization. All synthesized compounds were evaluated for their anti-HBV activity and toxicity in human hepatocytes, lymphocytes and other cells. Additionally, we assessed their effect on HBV cccDNA formation in an HBeAg reporter cell-based assay. Among the 27 compounds reported, several analogs exhibited submicromolar activities and significant reduction of HBeAg secretion. Selected compounds were studied under negative-stain electron microscopy for their ability to disrupt the HBV capsid formation. Structures were modeled into a binding site recently identified in the HBV capsid protein for similar molecules to rationalize the structure-activity relationships for this family of compounds.

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

NITROGENOUS FUSED?RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.